Abstract

We assessed the use of ultrasound (US)-guided photoacoustic imaging (PAI) and anti-EGFR antibody-conjugated gold nanorods (anti-EGFR-GNs) to non-invasively detect EGFR-expressing primary tumor masses and regional lymph node (LN) metastases in breast tumor mice generated by injecting MCF-7 (EGFR-negative) or MDA-MB-231 (EGFR-positive) human breast cells using a preclinical Vevo 2100 LAZR Imaging system. Anti-EGFR-GNs provided a significant enhancement in the PA signal in MDA-MB-231 tumor and the axillary LN metastases relative to MCF-7 tumor and non-LN metastases. We demonstrated that US-guided PAI using anti-EGFR-GNs is highly sensitive for the selective visualization of EGFR-expressing breast primary tumors as well as LN micrometastases.

© 2016 Optical Society of America

Full Article  |  PDF Article
OSA Recommended Articles
High-resolution fiber optic microscopy with fluorescent contrast enhancement for the identification of axillary lymph node metastases in breast cancer: a pilot study

Kelsey J. Rosbach, Dongsuk Shin, Timothy J. Muldoon, Mohammad A. Quraishi, Lavinia P. Middleton, Kelly K. Hunt, Funda Meric-Bernstam, Tse-Kuan Yu, Rebecca R. Richards-Kortum, and Wei Yang
Biomed. Opt. Express 1(3) 911-922 (2010)

Toward nodal staging of axillary lymph node basins through intradermal administration of fluorescent imaging agents

Funda Meric-Bernstam, John C. Rasmussen, Savitri Krishnamurthy, I-Chih Tan, Banghe Zhu, Jamie L. Wagner, Gildy V. Babiera, Elizabeth A. Mittendorf, and Eva M. Sevick-Muraca
Biomed. Opt. Express 5(1) 183-196 (2014)

In vivo Photoacoustic Molecular Imaging with Simultaneous Multiple Selective Targeting Using Antibody-Conjugated Gold Nanorods

Pai-Chi Li, Churng-Ren Chris Wang, Dar-Bin Shieh, Chen-Wei Wei, Chao-Kang Liao, Carolina Poe, Suwen Jhan, Ann-Ann Ding, and Ya-Na Wu
Opt. Express 16(23) 18605-18615 (2008)

References

  • View by:
  • |
  • |
  • |

  1. J. M. Wu, M. J. Fackler, M. K. Halushka, D. W. Molavi, M. E. Taylor, W. W. Teo, C. Griffin, J. Fetting, N. E. Davidson, A. M. De Marzo, J. L. Hicks, D. Chitale, M. Ladanyi, S. Sukumar, and P. Argani, “Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases,” Clin. Cancer Res. 14(7), 1938–1946 (2008).
    [Crossref] [PubMed]
  2. L. A. Carey, H. S. Rugo, P. K. Marcom, E. L. Mayer, F. J. Esteva, C. X. Ma, M. C. Liu, A. M. Storniolo, M. F. Rimawi, A. Forero-Torres, A. C. Wolff, T. J. Hobday, A. Ivanova, W. K. Chiu, M. Ferraro, E. Burrows, P. S. Bernard, K. A. Hoadley, C. M. Perou, and E. P. Winer, “TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer,” J. Clin. Oncol. 30(21), 2615–2623 (2012).
    [Crossref] [PubMed]
  3. D. A. Ferraro, N. Gaborit, R. Maron, H. Cohen-Dvashi, Z. Porat, F. Pareja, S. Lavi, M. Lindzen, N. Ben-Chetrit, M. Sela, and Y. Yarden, “Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR,” Proc. Natl. Acad. Sci. U.S.A. 110(5), 1815–1820 (2013).
    [Crossref] [PubMed]
  4. J. Graham, M. Muhsin, and P. Kirkpatrick, “Cetuximab,” Nat. Rev. Drug Discov. 3(7), 549–550 (2004).
    [Crossref] [PubMed]
  5. L. V. Wang and S. Hu, “Photoacoustic tomography: in vivo imaging from organelles to organs,” Science 335(6075), 1458–1462 (2012).
    [Crossref] [PubMed]
  6. M. Eghtedari, A. Oraevsky, J. A. Copland, N. A. Kotov, A. Conjusteau, and M. Motamedi, “High sensitivity of in vivo detection of gold nanorods using a laser optoacoustic imaging system,” Nano Lett. 7(7), 1914–1918 (2007).
    [Crossref] [PubMed]
  7. G. P. Luke, D. Yeager, and S. Y. Emelianov, “Biomedical applications of photoacoustic imaging with exogenous contrast agents,” Ann. Biomed. Eng. 40(2), 422–437 (2012).
    [Crossref] [PubMed]
  8. R. I. Siphanto, K. K. Thumma, R. G. Kolkman, T. G. van Leeuwen, F. F. de Mul, J. W. van Neck, L. N. van Adrichem, and W. Steenbergen, “Serial noninvasive photoacoustic imaging of neovascularization in tumor angiogenesis,” Opt. Express 13(1), 89–95 (2005).
    [Crossref] [PubMed]
  9. Q. Zhang, N. Iwakuma, P. Sharma, B. M. Moudgil, C. Wu, J. McNeill, H. Jiang, and S. R. Grobmyer, “Gold nanoparticles as a contrast agent for in vivo tumor imaging with photoacoustic tomography,” Nanotechnology 20(39), 395102 (2009).
    [Crossref] [PubMed]
  10. S. Jain, D. G. Hirst, and J. M. O’Sullivan, “Gold nanoparticles as novel agents for cancer therapy,” Br. J. Radiol. 85(1010), 101–113 (2012).
    [Crossref] [PubMed]
  11. N. Khlebtsov and L. Dykman, “Biodistribution and toxicity of engineered gold nanoparticles: a review of in vitro and in vivo studies,” Chem. Soc. Rev. 40(3), 1647–1671 (2011).
    [Crossref] [PubMed]
  12. S. Manohar, C. Ungureanu, and T. G. Van Leeuwen, “Gold nanorods as molecular contrast agents in photoacoustic imaging: the promises and the caveats,” Contrast Media Mol. Imaging 6(5), 389–400 (2011).
    [Crossref] [PubMed]
  13. G. P. Luke, J. N. Myers, S. Y. Emelianov, and K. V. Sokolov, “Sentinel lymph node biopsy revisited: ultrasound-guided photoacoustic detection of micrometastases using molecularly targeted plasmonic nanosensors,” Cancer Res. 74(19), 5397–5408 (2014).
    [Crossref] [PubMed]
  14. M. M. Jensen, J. T. Jørgensen, T. Binderup, and A. Kjaer, “Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper,” BMC Med. Imaging 8(1), 16 (2008).
    [Crossref] [PubMed]
  15. X. Cai, W. Li, C. H. Kim, Y. Yuan, L. V. Wang, and Y. Xia, “In vivo quantitative evaluation of the transport kinetics of gold nanocages in a lymphatic system by noninvasive photoacoustic tomography,” ACS Nano 5(12), 9658–9667 (2011).
    [Crossref] [PubMed]
  16. H. Kobayashi, S. Kawamoto, Y. Sakai, P. L. Choyke, R. A. Star, M. W. Brechbiel, N. Sato, Y. Tagaya, J. C. Morris, and T. A. Waldmann, “Lymphatic drainage imaging of breast cancer in mice by micro-magnetic resonance lymphangiography using a nano-size paramagnetic contrast agent,” J. Natl. Cancer Inst. 96(9), 703–708 (2004).
    [Crossref] [PubMed]
  17. F. Amersi and N. M. Hansen, “The benefits and limitations of sentinel lymph node biopsy,” Curr. Treat. Options Oncol. 7(2), 141–151 (2006).
    [Crossref] [PubMed]
  18. L. Bergkvist, J. Frisell, G. Swedish, Swedish Breast Cancer GroupSwedish Society of Breast Surgeons, “Multicentre validation study of sentinel node biopsy for staging in breast cancer,” Br. J. Surg. 92(10), 1221–1224 (2005).
    [Crossref] [PubMed]
  19. R. Rönkä, K. Smitten, H. Sintonen, T. Kotomäki, L. Krogerus, E. Leppänen, and M. Leidenius, “The impact of sentinel node biopsy and axillary staging strategy on hospital costs,” Ann. Oncol. 15(1), 88–94 (2004).
    [Crossref] [PubMed]
  20. J. Chen and J. Irudayaraj, “Quantitative investigation of compartmentalized dynamics of ErbB2 targeting gold nanorods in live cells by single molecule spectroscopy,” ACS Nano 3(12), 4071–4079 (2009).
    [Crossref] [PubMed]
  21. G. P. Luke and S. Y. Emelianov, “Label-free Detection of Lymph Node Metastases with US-guided Functional Photoacoustic Imaging,” Radiology 277(2), 435–442 (2015).
    [Crossref] [PubMed]
  22. C. R. Patra, R. Bhattacharya, E. Wang, A. Katarya, J. S. Lau, S. Dutta, M. Muders, S. Wang, S. A. Buhrow, S. L. Safgren, M. J. Yaszemski, J. M. Reid, M. M. Ames, P. Mukherjee, and D. Mukhopadhyay, “Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent,” Cancer Res. 68(6), 1970–1978 (2008).
    [Crossref] [PubMed]

2015 (1)

G. P. Luke and S. Y. Emelianov, “Label-free Detection of Lymph Node Metastases with US-guided Functional Photoacoustic Imaging,” Radiology 277(2), 435–442 (2015).
[Crossref] [PubMed]

2014 (1)

G. P. Luke, J. N. Myers, S. Y. Emelianov, and K. V. Sokolov, “Sentinel lymph node biopsy revisited: ultrasound-guided photoacoustic detection of micrometastases using molecularly targeted plasmonic nanosensors,” Cancer Res. 74(19), 5397–5408 (2014).
[Crossref] [PubMed]

2013 (1)

D. A. Ferraro, N. Gaborit, R. Maron, H. Cohen-Dvashi, Z. Porat, F. Pareja, S. Lavi, M. Lindzen, N. Ben-Chetrit, M. Sela, and Y. Yarden, “Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR,” Proc. Natl. Acad. Sci. U.S.A. 110(5), 1815–1820 (2013).
[Crossref] [PubMed]

2012 (4)

L. A. Carey, H. S. Rugo, P. K. Marcom, E. L. Mayer, F. J. Esteva, C. X. Ma, M. C. Liu, A. M. Storniolo, M. F. Rimawi, A. Forero-Torres, A. C. Wolff, T. J. Hobday, A. Ivanova, W. K. Chiu, M. Ferraro, E. Burrows, P. S. Bernard, K. A. Hoadley, C. M. Perou, and E. P. Winer, “TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer,” J. Clin. Oncol. 30(21), 2615–2623 (2012).
[Crossref] [PubMed]

L. V. Wang and S. Hu, “Photoacoustic tomography: in vivo imaging from organelles to organs,” Science 335(6075), 1458–1462 (2012).
[Crossref] [PubMed]

G. P. Luke, D. Yeager, and S. Y. Emelianov, “Biomedical applications of photoacoustic imaging with exogenous contrast agents,” Ann. Biomed. Eng. 40(2), 422–437 (2012).
[Crossref] [PubMed]

S. Jain, D. G. Hirst, and J. M. O’Sullivan, “Gold nanoparticles as novel agents for cancer therapy,” Br. J. Radiol. 85(1010), 101–113 (2012).
[Crossref] [PubMed]

2011 (3)

N. Khlebtsov and L. Dykman, “Biodistribution and toxicity of engineered gold nanoparticles: a review of in vitro and in vivo studies,” Chem. Soc. Rev. 40(3), 1647–1671 (2011).
[Crossref] [PubMed]

S. Manohar, C. Ungureanu, and T. G. Van Leeuwen, “Gold nanorods as molecular contrast agents in photoacoustic imaging: the promises and the caveats,” Contrast Media Mol. Imaging 6(5), 389–400 (2011).
[Crossref] [PubMed]

X. Cai, W. Li, C. H. Kim, Y. Yuan, L. V. Wang, and Y. Xia, “In vivo quantitative evaluation of the transport kinetics of gold nanocages in a lymphatic system by noninvasive photoacoustic tomography,” ACS Nano 5(12), 9658–9667 (2011).
[Crossref] [PubMed]

2009 (2)

Q. Zhang, N. Iwakuma, P. Sharma, B. M. Moudgil, C. Wu, J. McNeill, H. Jiang, and S. R. Grobmyer, “Gold nanoparticles as a contrast agent for in vivo tumor imaging with photoacoustic tomography,” Nanotechnology 20(39), 395102 (2009).
[Crossref] [PubMed]

J. Chen and J. Irudayaraj, “Quantitative investigation of compartmentalized dynamics of ErbB2 targeting gold nanorods in live cells by single molecule spectroscopy,” ACS Nano 3(12), 4071–4079 (2009).
[Crossref] [PubMed]

2008 (3)

C. R. Patra, R. Bhattacharya, E. Wang, A. Katarya, J. S. Lau, S. Dutta, M. Muders, S. Wang, S. A. Buhrow, S. L. Safgren, M. J. Yaszemski, J. M. Reid, M. M. Ames, P. Mukherjee, and D. Mukhopadhyay, “Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent,” Cancer Res. 68(6), 1970–1978 (2008).
[Crossref] [PubMed]

J. M. Wu, M. J. Fackler, M. K. Halushka, D. W. Molavi, M. E. Taylor, W. W. Teo, C. Griffin, J. Fetting, N. E. Davidson, A. M. De Marzo, J. L. Hicks, D. Chitale, M. Ladanyi, S. Sukumar, and P. Argani, “Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases,” Clin. Cancer Res. 14(7), 1938–1946 (2008).
[Crossref] [PubMed]

M. M. Jensen, J. T. Jørgensen, T. Binderup, and A. Kjaer, “Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper,” BMC Med. Imaging 8(1), 16 (2008).
[Crossref] [PubMed]

2007 (1)

M. Eghtedari, A. Oraevsky, J. A. Copland, N. A. Kotov, A. Conjusteau, and M. Motamedi, “High sensitivity of in vivo detection of gold nanorods using a laser optoacoustic imaging system,” Nano Lett. 7(7), 1914–1918 (2007).
[Crossref] [PubMed]

2006 (1)

F. Amersi and N. M. Hansen, “The benefits and limitations of sentinel lymph node biopsy,” Curr. Treat. Options Oncol. 7(2), 141–151 (2006).
[Crossref] [PubMed]

2005 (2)

L. Bergkvist, J. Frisell, G. Swedish, Swedish Breast Cancer GroupSwedish Society of Breast Surgeons, “Multicentre validation study of sentinel node biopsy for staging in breast cancer,” Br. J. Surg. 92(10), 1221–1224 (2005).
[Crossref] [PubMed]

R. I. Siphanto, K. K. Thumma, R. G. Kolkman, T. G. van Leeuwen, F. F. de Mul, J. W. van Neck, L. N. van Adrichem, and W. Steenbergen, “Serial noninvasive photoacoustic imaging of neovascularization in tumor angiogenesis,” Opt. Express 13(1), 89–95 (2005).
[Crossref] [PubMed]

2004 (3)

R. Rönkä, K. Smitten, H. Sintonen, T. Kotomäki, L. Krogerus, E. Leppänen, and M. Leidenius, “The impact of sentinel node biopsy and axillary staging strategy on hospital costs,” Ann. Oncol. 15(1), 88–94 (2004).
[Crossref] [PubMed]

H. Kobayashi, S. Kawamoto, Y. Sakai, P. L. Choyke, R. A. Star, M. W. Brechbiel, N. Sato, Y. Tagaya, J. C. Morris, and T. A. Waldmann, “Lymphatic drainage imaging of breast cancer in mice by micro-magnetic resonance lymphangiography using a nano-size paramagnetic contrast agent,” J. Natl. Cancer Inst. 96(9), 703–708 (2004).
[Crossref] [PubMed]

J. Graham, M. Muhsin, and P. Kirkpatrick, “Cetuximab,” Nat. Rev. Drug Discov. 3(7), 549–550 (2004).
[Crossref] [PubMed]

Amersi, F.

F. Amersi and N. M. Hansen, “The benefits and limitations of sentinel lymph node biopsy,” Curr. Treat. Options Oncol. 7(2), 141–151 (2006).
[Crossref] [PubMed]

Ames, M. M.

C. R. Patra, R. Bhattacharya, E. Wang, A. Katarya, J. S. Lau, S. Dutta, M. Muders, S. Wang, S. A. Buhrow, S. L. Safgren, M. J. Yaszemski, J. M. Reid, M. M. Ames, P. Mukherjee, and D. Mukhopadhyay, “Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent,” Cancer Res. 68(6), 1970–1978 (2008).
[Crossref] [PubMed]

Argani, P.

J. M. Wu, M. J. Fackler, M. K. Halushka, D. W. Molavi, M. E. Taylor, W. W. Teo, C. Griffin, J. Fetting, N. E. Davidson, A. M. De Marzo, J. L. Hicks, D. Chitale, M. Ladanyi, S. Sukumar, and P. Argani, “Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases,” Clin. Cancer Res. 14(7), 1938–1946 (2008).
[Crossref] [PubMed]

Ben-Chetrit, N.

D. A. Ferraro, N. Gaborit, R. Maron, H. Cohen-Dvashi, Z. Porat, F. Pareja, S. Lavi, M. Lindzen, N. Ben-Chetrit, M. Sela, and Y. Yarden, “Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR,” Proc. Natl. Acad. Sci. U.S.A. 110(5), 1815–1820 (2013).
[Crossref] [PubMed]

Bergkvist, L.

L. Bergkvist, J. Frisell, G. Swedish, Swedish Breast Cancer GroupSwedish Society of Breast Surgeons, “Multicentre validation study of sentinel node biopsy for staging in breast cancer,” Br. J. Surg. 92(10), 1221–1224 (2005).
[Crossref] [PubMed]

Bernard, P. S.

L. A. Carey, H. S. Rugo, P. K. Marcom, E. L. Mayer, F. J. Esteva, C. X. Ma, M. C. Liu, A. M. Storniolo, M. F. Rimawi, A. Forero-Torres, A. C. Wolff, T. J. Hobday, A. Ivanova, W. K. Chiu, M. Ferraro, E. Burrows, P. S. Bernard, K. A. Hoadley, C. M. Perou, and E. P. Winer, “TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer,” J. Clin. Oncol. 30(21), 2615–2623 (2012).
[Crossref] [PubMed]

Bhattacharya, R.

C. R. Patra, R. Bhattacharya, E. Wang, A. Katarya, J. S. Lau, S. Dutta, M. Muders, S. Wang, S. A. Buhrow, S. L. Safgren, M. J. Yaszemski, J. M. Reid, M. M. Ames, P. Mukherjee, and D. Mukhopadhyay, “Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent,” Cancer Res. 68(6), 1970–1978 (2008).
[Crossref] [PubMed]

Binderup, T.

M. M. Jensen, J. T. Jørgensen, T. Binderup, and A. Kjaer, “Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper,” BMC Med. Imaging 8(1), 16 (2008).
[Crossref] [PubMed]

Brechbiel, M. W.

H. Kobayashi, S. Kawamoto, Y. Sakai, P. L. Choyke, R. A. Star, M. W. Brechbiel, N. Sato, Y. Tagaya, J. C. Morris, and T. A. Waldmann, “Lymphatic drainage imaging of breast cancer in mice by micro-magnetic resonance lymphangiography using a nano-size paramagnetic contrast agent,” J. Natl. Cancer Inst. 96(9), 703–708 (2004).
[Crossref] [PubMed]

Buhrow, S. A.

C. R. Patra, R. Bhattacharya, E. Wang, A. Katarya, J. S. Lau, S. Dutta, M. Muders, S. Wang, S. A. Buhrow, S. L. Safgren, M. J. Yaszemski, J. M. Reid, M. M. Ames, P. Mukherjee, and D. Mukhopadhyay, “Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent,” Cancer Res. 68(6), 1970–1978 (2008).
[Crossref] [PubMed]

Burrows, E.

L. A. Carey, H. S. Rugo, P. K. Marcom, E. L. Mayer, F. J. Esteva, C. X. Ma, M. C. Liu, A. M. Storniolo, M. F. Rimawi, A. Forero-Torres, A. C. Wolff, T. J. Hobday, A. Ivanova, W. K. Chiu, M. Ferraro, E. Burrows, P. S. Bernard, K. A. Hoadley, C. M. Perou, and E. P. Winer, “TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer,” J. Clin. Oncol. 30(21), 2615–2623 (2012).
[Crossref] [PubMed]

Cai, X.

X. Cai, W. Li, C. H. Kim, Y. Yuan, L. V. Wang, and Y. Xia, “In vivo quantitative evaluation of the transport kinetics of gold nanocages in a lymphatic system by noninvasive photoacoustic tomography,” ACS Nano 5(12), 9658–9667 (2011).
[Crossref] [PubMed]

Carey, L. A.

L. A. Carey, H. S. Rugo, P. K. Marcom, E. L. Mayer, F. J. Esteva, C. X. Ma, M. C. Liu, A. M. Storniolo, M. F. Rimawi, A. Forero-Torres, A. C. Wolff, T. J. Hobday, A. Ivanova, W. K. Chiu, M. Ferraro, E. Burrows, P. S. Bernard, K. A. Hoadley, C. M. Perou, and E. P. Winer, “TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer,” J. Clin. Oncol. 30(21), 2615–2623 (2012).
[Crossref] [PubMed]

Chen, J.

J. Chen and J. Irudayaraj, “Quantitative investigation of compartmentalized dynamics of ErbB2 targeting gold nanorods in live cells by single molecule spectroscopy,” ACS Nano 3(12), 4071–4079 (2009).
[Crossref] [PubMed]

Chitale, D.

J. M. Wu, M. J. Fackler, M. K. Halushka, D. W. Molavi, M. E. Taylor, W. W. Teo, C. Griffin, J. Fetting, N. E. Davidson, A. M. De Marzo, J. L. Hicks, D. Chitale, M. Ladanyi, S. Sukumar, and P. Argani, “Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases,” Clin. Cancer Res. 14(7), 1938–1946 (2008).
[Crossref] [PubMed]

Chiu, W. K.

L. A. Carey, H. S. Rugo, P. K. Marcom, E. L. Mayer, F. J. Esteva, C. X. Ma, M. C. Liu, A. M. Storniolo, M. F. Rimawi, A. Forero-Torres, A. C. Wolff, T. J. Hobday, A. Ivanova, W. K. Chiu, M. Ferraro, E. Burrows, P. S. Bernard, K. A. Hoadley, C. M. Perou, and E. P. Winer, “TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer,” J. Clin. Oncol. 30(21), 2615–2623 (2012).
[Crossref] [PubMed]

Choyke, P. L.

H. Kobayashi, S. Kawamoto, Y. Sakai, P. L. Choyke, R. A. Star, M. W. Brechbiel, N. Sato, Y. Tagaya, J. C. Morris, and T. A. Waldmann, “Lymphatic drainage imaging of breast cancer in mice by micro-magnetic resonance lymphangiography using a nano-size paramagnetic contrast agent,” J. Natl. Cancer Inst. 96(9), 703–708 (2004).
[Crossref] [PubMed]

Cohen-Dvashi, H.

D. A. Ferraro, N. Gaborit, R. Maron, H. Cohen-Dvashi, Z. Porat, F. Pareja, S. Lavi, M. Lindzen, N. Ben-Chetrit, M. Sela, and Y. Yarden, “Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR,” Proc. Natl. Acad. Sci. U.S.A. 110(5), 1815–1820 (2013).
[Crossref] [PubMed]

Conjusteau, A.

M. Eghtedari, A. Oraevsky, J. A. Copland, N. A. Kotov, A. Conjusteau, and M. Motamedi, “High sensitivity of in vivo detection of gold nanorods using a laser optoacoustic imaging system,” Nano Lett. 7(7), 1914–1918 (2007).
[Crossref] [PubMed]

Copland, J. A.

M. Eghtedari, A. Oraevsky, J. A. Copland, N. A. Kotov, A. Conjusteau, and M. Motamedi, “High sensitivity of in vivo detection of gold nanorods using a laser optoacoustic imaging system,” Nano Lett. 7(7), 1914–1918 (2007).
[Crossref] [PubMed]

Davidson, N. E.

J. M. Wu, M. J. Fackler, M. K. Halushka, D. W. Molavi, M. E. Taylor, W. W. Teo, C. Griffin, J. Fetting, N. E. Davidson, A. M. De Marzo, J. L. Hicks, D. Chitale, M. Ladanyi, S. Sukumar, and P. Argani, “Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases,” Clin. Cancer Res. 14(7), 1938–1946 (2008).
[Crossref] [PubMed]

De Marzo, A. M.

J. M. Wu, M. J. Fackler, M. K. Halushka, D. W. Molavi, M. E. Taylor, W. W. Teo, C. Griffin, J. Fetting, N. E. Davidson, A. M. De Marzo, J. L. Hicks, D. Chitale, M. Ladanyi, S. Sukumar, and P. Argani, “Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases,” Clin. Cancer Res. 14(7), 1938–1946 (2008).
[Crossref] [PubMed]

de Mul, F. F.

Dutta, S.

C. R. Patra, R. Bhattacharya, E. Wang, A. Katarya, J. S. Lau, S. Dutta, M. Muders, S. Wang, S. A. Buhrow, S. L. Safgren, M. J. Yaszemski, J. M. Reid, M. M. Ames, P. Mukherjee, and D. Mukhopadhyay, “Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent,” Cancer Res. 68(6), 1970–1978 (2008).
[Crossref] [PubMed]

Dykman, L.

N. Khlebtsov and L. Dykman, “Biodistribution and toxicity of engineered gold nanoparticles: a review of in vitro and in vivo studies,” Chem. Soc. Rev. 40(3), 1647–1671 (2011).
[Crossref] [PubMed]

Eghtedari, M.

M. Eghtedari, A. Oraevsky, J. A. Copland, N. A. Kotov, A. Conjusteau, and M. Motamedi, “High sensitivity of in vivo detection of gold nanorods using a laser optoacoustic imaging system,” Nano Lett. 7(7), 1914–1918 (2007).
[Crossref] [PubMed]

Emelianov, S. Y.

G. P. Luke and S. Y. Emelianov, “Label-free Detection of Lymph Node Metastases with US-guided Functional Photoacoustic Imaging,” Radiology 277(2), 435–442 (2015).
[Crossref] [PubMed]

G. P. Luke, J. N. Myers, S. Y. Emelianov, and K. V. Sokolov, “Sentinel lymph node biopsy revisited: ultrasound-guided photoacoustic detection of micrometastases using molecularly targeted plasmonic nanosensors,” Cancer Res. 74(19), 5397–5408 (2014).
[Crossref] [PubMed]

G. P. Luke, D. Yeager, and S. Y. Emelianov, “Biomedical applications of photoacoustic imaging with exogenous contrast agents,” Ann. Biomed. Eng. 40(2), 422–437 (2012).
[Crossref] [PubMed]

Esteva, F. J.

L. A. Carey, H. S. Rugo, P. K. Marcom, E. L. Mayer, F. J. Esteva, C. X. Ma, M. C. Liu, A. M. Storniolo, M. F. Rimawi, A. Forero-Torres, A. C. Wolff, T. J. Hobday, A. Ivanova, W. K. Chiu, M. Ferraro, E. Burrows, P. S. Bernard, K. A. Hoadley, C. M. Perou, and E. P. Winer, “TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer,” J. Clin. Oncol. 30(21), 2615–2623 (2012).
[Crossref] [PubMed]

Fackler, M. J.

J. M. Wu, M. J. Fackler, M. K. Halushka, D. W. Molavi, M. E. Taylor, W. W. Teo, C. Griffin, J. Fetting, N. E. Davidson, A. M. De Marzo, J. L. Hicks, D. Chitale, M. Ladanyi, S. Sukumar, and P. Argani, “Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases,” Clin. Cancer Res. 14(7), 1938–1946 (2008).
[Crossref] [PubMed]

Ferraro, D. A.

D. A. Ferraro, N. Gaborit, R. Maron, H. Cohen-Dvashi, Z. Porat, F. Pareja, S. Lavi, M. Lindzen, N. Ben-Chetrit, M. Sela, and Y. Yarden, “Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR,” Proc. Natl. Acad. Sci. U.S.A. 110(5), 1815–1820 (2013).
[Crossref] [PubMed]

Ferraro, M.

L. A. Carey, H. S. Rugo, P. K. Marcom, E. L. Mayer, F. J. Esteva, C. X. Ma, M. C. Liu, A. M. Storniolo, M. F. Rimawi, A. Forero-Torres, A. C. Wolff, T. J. Hobday, A. Ivanova, W. K. Chiu, M. Ferraro, E. Burrows, P. S. Bernard, K. A. Hoadley, C. M. Perou, and E. P. Winer, “TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer,” J. Clin. Oncol. 30(21), 2615–2623 (2012).
[Crossref] [PubMed]

Fetting, J.

J. M. Wu, M. J. Fackler, M. K. Halushka, D. W. Molavi, M. E. Taylor, W. W. Teo, C. Griffin, J. Fetting, N. E. Davidson, A. M. De Marzo, J. L. Hicks, D. Chitale, M. Ladanyi, S. Sukumar, and P. Argani, “Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases,” Clin. Cancer Res. 14(7), 1938–1946 (2008).
[Crossref] [PubMed]

Forero-Torres, A.

L. A. Carey, H. S. Rugo, P. K. Marcom, E. L. Mayer, F. J. Esteva, C. X. Ma, M. C. Liu, A. M. Storniolo, M. F. Rimawi, A. Forero-Torres, A. C. Wolff, T. J. Hobday, A. Ivanova, W. K. Chiu, M. Ferraro, E. Burrows, P. S. Bernard, K. A. Hoadley, C. M. Perou, and E. P. Winer, “TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer,” J. Clin. Oncol. 30(21), 2615–2623 (2012).
[Crossref] [PubMed]

Frisell, J.

L. Bergkvist, J. Frisell, G. Swedish, Swedish Breast Cancer GroupSwedish Society of Breast Surgeons, “Multicentre validation study of sentinel node biopsy for staging in breast cancer,” Br. J. Surg. 92(10), 1221–1224 (2005).
[Crossref] [PubMed]

Gaborit, N.

D. A. Ferraro, N. Gaborit, R. Maron, H. Cohen-Dvashi, Z. Porat, F. Pareja, S. Lavi, M. Lindzen, N. Ben-Chetrit, M. Sela, and Y. Yarden, “Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR,” Proc. Natl. Acad. Sci. U.S.A. 110(5), 1815–1820 (2013).
[Crossref] [PubMed]

Graham, J.

J. Graham, M. Muhsin, and P. Kirkpatrick, “Cetuximab,” Nat. Rev. Drug Discov. 3(7), 549–550 (2004).
[Crossref] [PubMed]

Griffin, C.

J. M. Wu, M. J. Fackler, M. K. Halushka, D. W. Molavi, M. E. Taylor, W. W. Teo, C. Griffin, J. Fetting, N. E. Davidson, A. M. De Marzo, J. L. Hicks, D. Chitale, M. Ladanyi, S. Sukumar, and P. Argani, “Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases,” Clin. Cancer Res. 14(7), 1938–1946 (2008).
[Crossref] [PubMed]

Grobmyer, S. R.

Q. Zhang, N. Iwakuma, P. Sharma, B. M. Moudgil, C. Wu, J. McNeill, H. Jiang, and S. R. Grobmyer, “Gold nanoparticles as a contrast agent for in vivo tumor imaging with photoacoustic tomography,” Nanotechnology 20(39), 395102 (2009).
[Crossref] [PubMed]

Halushka, M. K.

J. M. Wu, M. J. Fackler, M. K. Halushka, D. W. Molavi, M. E. Taylor, W. W. Teo, C. Griffin, J. Fetting, N. E. Davidson, A. M. De Marzo, J. L. Hicks, D. Chitale, M. Ladanyi, S. Sukumar, and P. Argani, “Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases,” Clin. Cancer Res. 14(7), 1938–1946 (2008).
[Crossref] [PubMed]

Hansen, N. M.

F. Amersi and N. M. Hansen, “The benefits and limitations of sentinel lymph node biopsy,” Curr. Treat. Options Oncol. 7(2), 141–151 (2006).
[Crossref] [PubMed]

Hicks, J. L.

J. M. Wu, M. J. Fackler, M. K. Halushka, D. W. Molavi, M. E. Taylor, W. W. Teo, C. Griffin, J. Fetting, N. E. Davidson, A. M. De Marzo, J. L. Hicks, D. Chitale, M. Ladanyi, S. Sukumar, and P. Argani, “Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases,” Clin. Cancer Res. 14(7), 1938–1946 (2008).
[Crossref] [PubMed]

Hirst, D. G.

S. Jain, D. G. Hirst, and J. M. O’Sullivan, “Gold nanoparticles as novel agents for cancer therapy,” Br. J. Radiol. 85(1010), 101–113 (2012).
[Crossref] [PubMed]

Hoadley, K. A.

L. A. Carey, H. S. Rugo, P. K. Marcom, E. L. Mayer, F. J. Esteva, C. X. Ma, M. C. Liu, A. M. Storniolo, M. F. Rimawi, A. Forero-Torres, A. C. Wolff, T. J. Hobday, A. Ivanova, W. K. Chiu, M. Ferraro, E. Burrows, P. S. Bernard, K. A. Hoadley, C. M. Perou, and E. P. Winer, “TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer,” J. Clin. Oncol. 30(21), 2615–2623 (2012).
[Crossref] [PubMed]

Hobday, T. J.

L. A. Carey, H. S. Rugo, P. K. Marcom, E. L. Mayer, F. J. Esteva, C. X. Ma, M. C. Liu, A. M. Storniolo, M. F. Rimawi, A. Forero-Torres, A. C. Wolff, T. J. Hobday, A. Ivanova, W. K. Chiu, M. Ferraro, E. Burrows, P. S. Bernard, K. A. Hoadley, C. M. Perou, and E. P. Winer, “TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer,” J. Clin. Oncol. 30(21), 2615–2623 (2012).
[Crossref] [PubMed]

Hu, S.

L. V. Wang and S. Hu, “Photoacoustic tomography: in vivo imaging from organelles to organs,” Science 335(6075), 1458–1462 (2012).
[Crossref] [PubMed]

Irudayaraj, J.

J. Chen and J. Irudayaraj, “Quantitative investigation of compartmentalized dynamics of ErbB2 targeting gold nanorods in live cells by single molecule spectroscopy,” ACS Nano 3(12), 4071–4079 (2009).
[Crossref] [PubMed]

Ivanova, A.

L. A. Carey, H. S. Rugo, P. K. Marcom, E. L. Mayer, F. J. Esteva, C. X. Ma, M. C. Liu, A. M. Storniolo, M. F. Rimawi, A. Forero-Torres, A. C. Wolff, T. J. Hobday, A. Ivanova, W. K. Chiu, M. Ferraro, E. Burrows, P. S. Bernard, K. A. Hoadley, C. M. Perou, and E. P. Winer, “TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer,” J. Clin. Oncol. 30(21), 2615–2623 (2012).
[Crossref] [PubMed]

Iwakuma, N.

Q. Zhang, N. Iwakuma, P. Sharma, B. M. Moudgil, C. Wu, J. McNeill, H. Jiang, and S. R. Grobmyer, “Gold nanoparticles as a contrast agent for in vivo tumor imaging with photoacoustic tomography,” Nanotechnology 20(39), 395102 (2009).
[Crossref] [PubMed]

Jain, S.

S. Jain, D. G. Hirst, and J. M. O’Sullivan, “Gold nanoparticles as novel agents for cancer therapy,” Br. J. Radiol. 85(1010), 101–113 (2012).
[Crossref] [PubMed]

Jensen, M. M.

M. M. Jensen, J. T. Jørgensen, T. Binderup, and A. Kjaer, “Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper,” BMC Med. Imaging 8(1), 16 (2008).
[Crossref] [PubMed]

Jiang, H.

Q. Zhang, N. Iwakuma, P. Sharma, B. M. Moudgil, C. Wu, J. McNeill, H. Jiang, and S. R. Grobmyer, “Gold nanoparticles as a contrast agent for in vivo tumor imaging with photoacoustic tomography,” Nanotechnology 20(39), 395102 (2009).
[Crossref] [PubMed]

Jørgensen, J. T.

M. M. Jensen, J. T. Jørgensen, T. Binderup, and A. Kjaer, “Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper,” BMC Med. Imaging 8(1), 16 (2008).
[Crossref] [PubMed]

Katarya, A.

C. R. Patra, R. Bhattacharya, E. Wang, A. Katarya, J. S. Lau, S. Dutta, M. Muders, S. Wang, S. A. Buhrow, S. L. Safgren, M. J. Yaszemski, J. M. Reid, M. M. Ames, P. Mukherjee, and D. Mukhopadhyay, “Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent,” Cancer Res. 68(6), 1970–1978 (2008).
[Crossref] [PubMed]

Kawamoto, S.

H. Kobayashi, S. Kawamoto, Y. Sakai, P. L. Choyke, R. A. Star, M. W. Brechbiel, N. Sato, Y. Tagaya, J. C. Morris, and T. A. Waldmann, “Lymphatic drainage imaging of breast cancer in mice by micro-magnetic resonance lymphangiography using a nano-size paramagnetic contrast agent,” J. Natl. Cancer Inst. 96(9), 703–708 (2004).
[Crossref] [PubMed]

Khlebtsov, N.

N. Khlebtsov and L. Dykman, “Biodistribution and toxicity of engineered gold nanoparticles: a review of in vitro and in vivo studies,” Chem. Soc. Rev. 40(3), 1647–1671 (2011).
[Crossref] [PubMed]

Kim, C. H.

X. Cai, W. Li, C. H. Kim, Y. Yuan, L. V. Wang, and Y. Xia, “In vivo quantitative evaluation of the transport kinetics of gold nanocages in a lymphatic system by noninvasive photoacoustic tomography,” ACS Nano 5(12), 9658–9667 (2011).
[Crossref] [PubMed]

Kirkpatrick, P.

J. Graham, M. Muhsin, and P. Kirkpatrick, “Cetuximab,” Nat. Rev. Drug Discov. 3(7), 549–550 (2004).
[Crossref] [PubMed]

Kjaer, A.

M. M. Jensen, J. T. Jørgensen, T. Binderup, and A. Kjaer, “Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper,” BMC Med. Imaging 8(1), 16 (2008).
[Crossref] [PubMed]

Kobayashi, H.

H. Kobayashi, S. Kawamoto, Y. Sakai, P. L. Choyke, R. A. Star, M. W. Brechbiel, N. Sato, Y. Tagaya, J. C. Morris, and T. A. Waldmann, “Lymphatic drainage imaging of breast cancer in mice by micro-magnetic resonance lymphangiography using a nano-size paramagnetic contrast agent,” J. Natl. Cancer Inst. 96(9), 703–708 (2004).
[Crossref] [PubMed]

Kolkman, R. G.

Kotomäki, T.

R. Rönkä, K. Smitten, H. Sintonen, T. Kotomäki, L. Krogerus, E. Leppänen, and M. Leidenius, “The impact of sentinel node biopsy and axillary staging strategy on hospital costs,” Ann. Oncol. 15(1), 88–94 (2004).
[Crossref] [PubMed]

Kotov, N. A.

M. Eghtedari, A. Oraevsky, J. A. Copland, N. A. Kotov, A. Conjusteau, and M. Motamedi, “High sensitivity of in vivo detection of gold nanorods using a laser optoacoustic imaging system,” Nano Lett. 7(7), 1914–1918 (2007).
[Crossref] [PubMed]

Krogerus, L.

R. Rönkä, K. Smitten, H. Sintonen, T. Kotomäki, L. Krogerus, E. Leppänen, and M. Leidenius, “The impact of sentinel node biopsy and axillary staging strategy on hospital costs,” Ann. Oncol. 15(1), 88–94 (2004).
[Crossref] [PubMed]

Ladanyi, M.

J. M. Wu, M. J. Fackler, M. K. Halushka, D. W. Molavi, M. E. Taylor, W. W. Teo, C. Griffin, J. Fetting, N. E. Davidson, A. M. De Marzo, J. L. Hicks, D. Chitale, M. Ladanyi, S. Sukumar, and P. Argani, “Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases,” Clin. Cancer Res. 14(7), 1938–1946 (2008).
[Crossref] [PubMed]

Lau, J. S.

C. R. Patra, R. Bhattacharya, E. Wang, A. Katarya, J. S. Lau, S. Dutta, M. Muders, S. Wang, S. A. Buhrow, S. L. Safgren, M. J. Yaszemski, J. M. Reid, M. M. Ames, P. Mukherjee, and D. Mukhopadhyay, “Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent,” Cancer Res. 68(6), 1970–1978 (2008).
[Crossref] [PubMed]

Lavi, S.

D. A. Ferraro, N. Gaborit, R. Maron, H. Cohen-Dvashi, Z. Porat, F. Pareja, S. Lavi, M. Lindzen, N. Ben-Chetrit, M. Sela, and Y. Yarden, “Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR,” Proc. Natl. Acad. Sci. U.S.A. 110(5), 1815–1820 (2013).
[Crossref] [PubMed]

Leidenius, M.

R. Rönkä, K. Smitten, H. Sintonen, T. Kotomäki, L. Krogerus, E. Leppänen, and M. Leidenius, “The impact of sentinel node biopsy and axillary staging strategy on hospital costs,” Ann. Oncol. 15(1), 88–94 (2004).
[Crossref] [PubMed]

Leppänen, E.

R. Rönkä, K. Smitten, H. Sintonen, T. Kotomäki, L. Krogerus, E. Leppänen, and M. Leidenius, “The impact of sentinel node biopsy and axillary staging strategy on hospital costs,” Ann. Oncol. 15(1), 88–94 (2004).
[Crossref] [PubMed]

Li, W.

X. Cai, W. Li, C. H. Kim, Y. Yuan, L. V. Wang, and Y. Xia, “In vivo quantitative evaluation of the transport kinetics of gold nanocages in a lymphatic system by noninvasive photoacoustic tomography,” ACS Nano 5(12), 9658–9667 (2011).
[Crossref] [PubMed]

Lindzen, M.

D. A. Ferraro, N. Gaborit, R. Maron, H. Cohen-Dvashi, Z. Porat, F. Pareja, S. Lavi, M. Lindzen, N. Ben-Chetrit, M. Sela, and Y. Yarden, “Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR,” Proc. Natl. Acad. Sci. U.S.A. 110(5), 1815–1820 (2013).
[Crossref] [PubMed]

Liu, M. C.

L. A. Carey, H. S. Rugo, P. K. Marcom, E. L. Mayer, F. J. Esteva, C. X. Ma, M. C. Liu, A. M. Storniolo, M. F. Rimawi, A. Forero-Torres, A. C. Wolff, T. J. Hobday, A. Ivanova, W. K. Chiu, M. Ferraro, E. Burrows, P. S. Bernard, K. A. Hoadley, C. M. Perou, and E. P. Winer, “TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer,” J. Clin. Oncol. 30(21), 2615–2623 (2012).
[Crossref] [PubMed]

Luke, G. P.

G. P. Luke and S. Y. Emelianov, “Label-free Detection of Lymph Node Metastases with US-guided Functional Photoacoustic Imaging,” Radiology 277(2), 435–442 (2015).
[Crossref] [PubMed]

G. P. Luke, J. N. Myers, S. Y. Emelianov, and K. V. Sokolov, “Sentinel lymph node biopsy revisited: ultrasound-guided photoacoustic detection of micrometastases using molecularly targeted plasmonic nanosensors,” Cancer Res. 74(19), 5397–5408 (2014).
[Crossref] [PubMed]

G. P. Luke, D. Yeager, and S. Y. Emelianov, “Biomedical applications of photoacoustic imaging with exogenous contrast agents,” Ann. Biomed. Eng. 40(2), 422–437 (2012).
[Crossref] [PubMed]

Ma, C. X.

L. A. Carey, H. S. Rugo, P. K. Marcom, E. L. Mayer, F. J. Esteva, C. X. Ma, M. C. Liu, A. M. Storniolo, M. F. Rimawi, A. Forero-Torres, A. C. Wolff, T. J. Hobday, A. Ivanova, W. K. Chiu, M. Ferraro, E. Burrows, P. S. Bernard, K. A. Hoadley, C. M. Perou, and E. P. Winer, “TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer,” J. Clin. Oncol. 30(21), 2615–2623 (2012).
[Crossref] [PubMed]

Manohar, S.

S. Manohar, C. Ungureanu, and T. G. Van Leeuwen, “Gold nanorods as molecular contrast agents in photoacoustic imaging: the promises and the caveats,” Contrast Media Mol. Imaging 6(5), 389–400 (2011).
[Crossref] [PubMed]

Marcom, P. K.

L. A. Carey, H. S. Rugo, P. K. Marcom, E. L. Mayer, F. J. Esteva, C. X. Ma, M. C. Liu, A. M. Storniolo, M. F. Rimawi, A. Forero-Torres, A. C. Wolff, T. J. Hobday, A. Ivanova, W. K. Chiu, M. Ferraro, E. Burrows, P. S. Bernard, K. A. Hoadley, C. M. Perou, and E. P. Winer, “TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer,” J. Clin. Oncol. 30(21), 2615–2623 (2012).
[Crossref] [PubMed]

Maron, R.

D. A. Ferraro, N. Gaborit, R. Maron, H. Cohen-Dvashi, Z. Porat, F. Pareja, S. Lavi, M. Lindzen, N. Ben-Chetrit, M. Sela, and Y. Yarden, “Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR,” Proc. Natl. Acad. Sci. U.S.A. 110(5), 1815–1820 (2013).
[Crossref] [PubMed]

Mayer, E. L.

L. A. Carey, H. S. Rugo, P. K. Marcom, E. L. Mayer, F. J. Esteva, C. X. Ma, M. C. Liu, A. M. Storniolo, M. F. Rimawi, A. Forero-Torres, A. C. Wolff, T. J. Hobday, A. Ivanova, W. K. Chiu, M. Ferraro, E. Burrows, P. S. Bernard, K. A. Hoadley, C. M. Perou, and E. P. Winer, “TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer,” J. Clin. Oncol. 30(21), 2615–2623 (2012).
[Crossref] [PubMed]

McNeill, J.

Q. Zhang, N. Iwakuma, P. Sharma, B. M. Moudgil, C. Wu, J. McNeill, H. Jiang, and S. R. Grobmyer, “Gold nanoparticles as a contrast agent for in vivo tumor imaging with photoacoustic tomography,” Nanotechnology 20(39), 395102 (2009).
[Crossref] [PubMed]

Molavi, D. W.

J. M. Wu, M. J. Fackler, M. K. Halushka, D. W. Molavi, M. E. Taylor, W. W. Teo, C. Griffin, J. Fetting, N. E. Davidson, A. M. De Marzo, J. L. Hicks, D. Chitale, M. Ladanyi, S. Sukumar, and P. Argani, “Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases,” Clin. Cancer Res. 14(7), 1938–1946 (2008).
[Crossref] [PubMed]

Morris, J. C.

H. Kobayashi, S. Kawamoto, Y. Sakai, P. L. Choyke, R. A. Star, M. W. Brechbiel, N. Sato, Y. Tagaya, J. C. Morris, and T. A. Waldmann, “Lymphatic drainage imaging of breast cancer in mice by micro-magnetic resonance lymphangiography using a nano-size paramagnetic contrast agent,” J. Natl. Cancer Inst. 96(9), 703–708 (2004).
[Crossref] [PubMed]

Motamedi, M.

M. Eghtedari, A. Oraevsky, J. A. Copland, N. A. Kotov, A. Conjusteau, and M. Motamedi, “High sensitivity of in vivo detection of gold nanorods using a laser optoacoustic imaging system,” Nano Lett. 7(7), 1914–1918 (2007).
[Crossref] [PubMed]

Moudgil, B. M.

Q. Zhang, N. Iwakuma, P. Sharma, B. M. Moudgil, C. Wu, J. McNeill, H. Jiang, and S. R. Grobmyer, “Gold nanoparticles as a contrast agent for in vivo tumor imaging with photoacoustic tomography,” Nanotechnology 20(39), 395102 (2009).
[Crossref] [PubMed]

Muders, M.

C. R. Patra, R. Bhattacharya, E. Wang, A. Katarya, J. S. Lau, S. Dutta, M. Muders, S. Wang, S. A. Buhrow, S. L. Safgren, M. J. Yaszemski, J. M. Reid, M. M. Ames, P. Mukherjee, and D. Mukhopadhyay, “Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent,” Cancer Res. 68(6), 1970–1978 (2008).
[Crossref] [PubMed]

Muhsin, M.

J. Graham, M. Muhsin, and P. Kirkpatrick, “Cetuximab,” Nat. Rev. Drug Discov. 3(7), 549–550 (2004).
[Crossref] [PubMed]

Mukherjee, P.

C. R. Patra, R. Bhattacharya, E. Wang, A. Katarya, J. S. Lau, S. Dutta, M. Muders, S. Wang, S. A. Buhrow, S. L. Safgren, M. J. Yaszemski, J. M. Reid, M. M. Ames, P. Mukherjee, and D. Mukhopadhyay, “Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent,” Cancer Res. 68(6), 1970–1978 (2008).
[Crossref] [PubMed]

Mukhopadhyay, D.

C. R. Patra, R. Bhattacharya, E. Wang, A. Katarya, J. S. Lau, S. Dutta, M. Muders, S. Wang, S. A. Buhrow, S. L. Safgren, M. J. Yaszemski, J. M. Reid, M. M. Ames, P. Mukherjee, and D. Mukhopadhyay, “Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent,” Cancer Res. 68(6), 1970–1978 (2008).
[Crossref] [PubMed]

Myers, J. N.

G. P. Luke, J. N. Myers, S. Y. Emelianov, and K. V. Sokolov, “Sentinel lymph node biopsy revisited: ultrasound-guided photoacoustic detection of micrometastases using molecularly targeted plasmonic nanosensors,” Cancer Res. 74(19), 5397–5408 (2014).
[Crossref] [PubMed]

O’Sullivan, J. M.

S. Jain, D. G. Hirst, and J. M. O’Sullivan, “Gold nanoparticles as novel agents for cancer therapy,” Br. J. Radiol. 85(1010), 101–113 (2012).
[Crossref] [PubMed]

Oraevsky, A.

M. Eghtedari, A. Oraevsky, J. A. Copland, N. A. Kotov, A. Conjusteau, and M. Motamedi, “High sensitivity of in vivo detection of gold nanorods using a laser optoacoustic imaging system,” Nano Lett. 7(7), 1914–1918 (2007).
[Crossref] [PubMed]

Pareja, F.

D. A. Ferraro, N. Gaborit, R. Maron, H. Cohen-Dvashi, Z. Porat, F. Pareja, S. Lavi, M. Lindzen, N. Ben-Chetrit, M. Sela, and Y. Yarden, “Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR,” Proc. Natl. Acad. Sci. U.S.A. 110(5), 1815–1820 (2013).
[Crossref] [PubMed]

Patra, C. R.

C. R. Patra, R. Bhattacharya, E. Wang, A. Katarya, J. S. Lau, S. Dutta, M. Muders, S. Wang, S. A. Buhrow, S. L. Safgren, M. J. Yaszemski, J. M. Reid, M. M. Ames, P. Mukherjee, and D. Mukhopadhyay, “Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent,” Cancer Res. 68(6), 1970–1978 (2008).
[Crossref] [PubMed]

Perou, C. M.

L. A. Carey, H. S. Rugo, P. K. Marcom, E. L. Mayer, F. J. Esteva, C. X. Ma, M. C. Liu, A. M. Storniolo, M. F. Rimawi, A. Forero-Torres, A. C. Wolff, T. J. Hobday, A. Ivanova, W. K. Chiu, M. Ferraro, E. Burrows, P. S. Bernard, K. A. Hoadley, C. M. Perou, and E. P. Winer, “TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer,” J. Clin. Oncol. 30(21), 2615–2623 (2012).
[Crossref] [PubMed]

Porat, Z.

D. A. Ferraro, N. Gaborit, R. Maron, H. Cohen-Dvashi, Z. Porat, F. Pareja, S. Lavi, M. Lindzen, N. Ben-Chetrit, M. Sela, and Y. Yarden, “Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR,” Proc. Natl. Acad. Sci. U.S.A. 110(5), 1815–1820 (2013).
[Crossref] [PubMed]

Reid, J. M.

C. R. Patra, R. Bhattacharya, E. Wang, A. Katarya, J. S. Lau, S. Dutta, M. Muders, S. Wang, S. A. Buhrow, S. L. Safgren, M. J. Yaszemski, J. M. Reid, M. M. Ames, P. Mukherjee, and D. Mukhopadhyay, “Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent,” Cancer Res. 68(6), 1970–1978 (2008).
[Crossref] [PubMed]

Rimawi, M. F.

L. A. Carey, H. S. Rugo, P. K. Marcom, E. L. Mayer, F. J. Esteva, C. X. Ma, M. C. Liu, A. M. Storniolo, M. F. Rimawi, A. Forero-Torres, A. C. Wolff, T. J. Hobday, A. Ivanova, W. K. Chiu, M. Ferraro, E. Burrows, P. S. Bernard, K. A. Hoadley, C. M. Perou, and E. P. Winer, “TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer,” J. Clin. Oncol. 30(21), 2615–2623 (2012).
[Crossref] [PubMed]

Rönkä, R.

R. Rönkä, K. Smitten, H. Sintonen, T. Kotomäki, L. Krogerus, E. Leppänen, and M. Leidenius, “The impact of sentinel node biopsy and axillary staging strategy on hospital costs,” Ann. Oncol. 15(1), 88–94 (2004).
[Crossref] [PubMed]

Rugo, H. S.

L. A. Carey, H. S. Rugo, P. K. Marcom, E. L. Mayer, F. J. Esteva, C. X. Ma, M. C. Liu, A. M. Storniolo, M. F. Rimawi, A. Forero-Torres, A. C. Wolff, T. J. Hobday, A. Ivanova, W. K. Chiu, M. Ferraro, E. Burrows, P. S. Bernard, K. A. Hoadley, C. M. Perou, and E. P. Winer, “TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer,” J. Clin. Oncol. 30(21), 2615–2623 (2012).
[Crossref] [PubMed]

Safgren, S. L.

C. R. Patra, R. Bhattacharya, E. Wang, A. Katarya, J. S. Lau, S. Dutta, M. Muders, S. Wang, S. A. Buhrow, S. L. Safgren, M. J. Yaszemski, J. M. Reid, M. M. Ames, P. Mukherjee, and D. Mukhopadhyay, “Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent,” Cancer Res. 68(6), 1970–1978 (2008).
[Crossref] [PubMed]

Sakai, Y.

H. Kobayashi, S. Kawamoto, Y. Sakai, P. L. Choyke, R. A. Star, M. W. Brechbiel, N. Sato, Y. Tagaya, J. C. Morris, and T. A. Waldmann, “Lymphatic drainage imaging of breast cancer in mice by micro-magnetic resonance lymphangiography using a nano-size paramagnetic contrast agent,” J. Natl. Cancer Inst. 96(9), 703–708 (2004).
[Crossref] [PubMed]

Sato, N.

H. Kobayashi, S. Kawamoto, Y. Sakai, P. L. Choyke, R. A. Star, M. W. Brechbiel, N. Sato, Y. Tagaya, J. C. Morris, and T. A. Waldmann, “Lymphatic drainage imaging of breast cancer in mice by micro-magnetic resonance lymphangiography using a nano-size paramagnetic contrast agent,” J. Natl. Cancer Inst. 96(9), 703–708 (2004).
[Crossref] [PubMed]

Sela, M.

D. A. Ferraro, N. Gaborit, R. Maron, H. Cohen-Dvashi, Z. Porat, F. Pareja, S. Lavi, M. Lindzen, N. Ben-Chetrit, M. Sela, and Y. Yarden, “Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR,” Proc. Natl. Acad. Sci. U.S.A. 110(5), 1815–1820 (2013).
[Crossref] [PubMed]

Sharma, P.

Q. Zhang, N. Iwakuma, P. Sharma, B. M. Moudgil, C. Wu, J. McNeill, H. Jiang, and S. R. Grobmyer, “Gold nanoparticles as a contrast agent for in vivo tumor imaging with photoacoustic tomography,” Nanotechnology 20(39), 395102 (2009).
[Crossref] [PubMed]

Sintonen, H.

R. Rönkä, K. Smitten, H. Sintonen, T. Kotomäki, L. Krogerus, E. Leppänen, and M. Leidenius, “The impact of sentinel node biopsy and axillary staging strategy on hospital costs,” Ann. Oncol. 15(1), 88–94 (2004).
[Crossref] [PubMed]

Siphanto, R. I.

Smitten, K.

R. Rönkä, K. Smitten, H. Sintonen, T. Kotomäki, L. Krogerus, E. Leppänen, and M. Leidenius, “The impact of sentinel node biopsy and axillary staging strategy on hospital costs,” Ann. Oncol. 15(1), 88–94 (2004).
[Crossref] [PubMed]

Sokolov, K. V.

G. P. Luke, J. N. Myers, S. Y. Emelianov, and K. V. Sokolov, “Sentinel lymph node biopsy revisited: ultrasound-guided photoacoustic detection of micrometastases using molecularly targeted plasmonic nanosensors,” Cancer Res. 74(19), 5397–5408 (2014).
[Crossref] [PubMed]

Star, R. A.

H. Kobayashi, S. Kawamoto, Y. Sakai, P. L. Choyke, R. A. Star, M. W. Brechbiel, N. Sato, Y. Tagaya, J. C. Morris, and T. A. Waldmann, “Lymphatic drainage imaging of breast cancer in mice by micro-magnetic resonance lymphangiography using a nano-size paramagnetic contrast agent,” J. Natl. Cancer Inst. 96(9), 703–708 (2004).
[Crossref] [PubMed]

Steenbergen, W.

Storniolo, A. M.

L. A. Carey, H. S. Rugo, P. K. Marcom, E. L. Mayer, F. J. Esteva, C. X. Ma, M. C. Liu, A. M. Storniolo, M. F. Rimawi, A. Forero-Torres, A. C. Wolff, T. J. Hobday, A. Ivanova, W. K. Chiu, M. Ferraro, E. Burrows, P. S. Bernard, K. A. Hoadley, C. M. Perou, and E. P. Winer, “TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer,” J. Clin. Oncol. 30(21), 2615–2623 (2012).
[Crossref] [PubMed]

Sukumar, S.

J. M. Wu, M. J. Fackler, M. K. Halushka, D. W. Molavi, M. E. Taylor, W. W. Teo, C. Griffin, J. Fetting, N. E. Davidson, A. M. De Marzo, J. L. Hicks, D. Chitale, M. Ladanyi, S. Sukumar, and P. Argani, “Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases,” Clin. Cancer Res. 14(7), 1938–1946 (2008).
[Crossref] [PubMed]

Swedish, G.

L. Bergkvist, J. Frisell, G. Swedish, Swedish Breast Cancer GroupSwedish Society of Breast Surgeons, “Multicentre validation study of sentinel node biopsy for staging in breast cancer,” Br. J. Surg. 92(10), 1221–1224 (2005).
[Crossref] [PubMed]

Tagaya, Y.

H. Kobayashi, S. Kawamoto, Y. Sakai, P. L. Choyke, R. A. Star, M. W. Brechbiel, N. Sato, Y. Tagaya, J. C. Morris, and T. A. Waldmann, “Lymphatic drainage imaging of breast cancer in mice by micro-magnetic resonance lymphangiography using a nano-size paramagnetic contrast agent,” J. Natl. Cancer Inst. 96(9), 703–708 (2004).
[Crossref] [PubMed]

Taylor, M. E.

J. M. Wu, M. J. Fackler, M. K. Halushka, D. W. Molavi, M. E. Taylor, W. W. Teo, C. Griffin, J. Fetting, N. E. Davidson, A. M. De Marzo, J. L. Hicks, D. Chitale, M. Ladanyi, S. Sukumar, and P. Argani, “Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases,” Clin. Cancer Res. 14(7), 1938–1946 (2008).
[Crossref] [PubMed]

Teo, W. W.

J. M. Wu, M. J. Fackler, M. K. Halushka, D. W. Molavi, M. E. Taylor, W. W. Teo, C. Griffin, J. Fetting, N. E. Davidson, A. M. De Marzo, J. L. Hicks, D. Chitale, M. Ladanyi, S. Sukumar, and P. Argani, “Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases,” Clin. Cancer Res. 14(7), 1938–1946 (2008).
[Crossref] [PubMed]

Thumma, K. K.

Ungureanu, C.

S. Manohar, C. Ungureanu, and T. G. Van Leeuwen, “Gold nanorods as molecular contrast agents in photoacoustic imaging: the promises and the caveats,” Contrast Media Mol. Imaging 6(5), 389–400 (2011).
[Crossref] [PubMed]

van Adrichem, L. N.

Van Leeuwen, T. G.

S. Manohar, C. Ungureanu, and T. G. Van Leeuwen, “Gold nanorods as molecular contrast agents in photoacoustic imaging: the promises and the caveats,” Contrast Media Mol. Imaging 6(5), 389–400 (2011).
[Crossref] [PubMed]

R. I. Siphanto, K. K. Thumma, R. G. Kolkman, T. G. van Leeuwen, F. F. de Mul, J. W. van Neck, L. N. van Adrichem, and W. Steenbergen, “Serial noninvasive photoacoustic imaging of neovascularization in tumor angiogenesis,” Opt. Express 13(1), 89–95 (2005).
[Crossref] [PubMed]

van Neck, J. W.

Waldmann, T. A.

H. Kobayashi, S. Kawamoto, Y. Sakai, P. L. Choyke, R. A. Star, M. W. Brechbiel, N. Sato, Y. Tagaya, J. C. Morris, and T. A. Waldmann, “Lymphatic drainage imaging of breast cancer in mice by micro-magnetic resonance lymphangiography using a nano-size paramagnetic contrast agent,” J. Natl. Cancer Inst. 96(9), 703–708 (2004).
[Crossref] [PubMed]

Wang, E.

C. R. Patra, R. Bhattacharya, E. Wang, A. Katarya, J. S. Lau, S. Dutta, M. Muders, S. Wang, S. A. Buhrow, S. L. Safgren, M. J. Yaszemski, J. M. Reid, M. M. Ames, P. Mukherjee, and D. Mukhopadhyay, “Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent,” Cancer Res. 68(6), 1970–1978 (2008).
[Crossref] [PubMed]

Wang, L. V.

L. V. Wang and S. Hu, “Photoacoustic tomography: in vivo imaging from organelles to organs,” Science 335(6075), 1458–1462 (2012).
[Crossref] [PubMed]

X. Cai, W. Li, C. H. Kim, Y. Yuan, L. V. Wang, and Y. Xia, “In vivo quantitative evaluation of the transport kinetics of gold nanocages in a lymphatic system by noninvasive photoacoustic tomography,” ACS Nano 5(12), 9658–9667 (2011).
[Crossref] [PubMed]

Wang, S.

C. R. Patra, R. Bhattacharya, E. Wang, A. Katarya, J. S. Lau, S. Dutta, M. Muders, S. Wang, S. A. Buhrow, S. L. Safgren, M. J. Yaszemski, J. M. Reid, M. M. Ames, P. Mukherjee, and D. Mukhopadhyay, “Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent,” Cancer Res. 68(6), 1970–1978 (2008).
[Crossref] [PubMed]

Winer, E. P.

L. A. Carey, H. S. Rugo, P. K. Marcom, E. L. Mayer, F. J. Esteva, C. X. Ma, M. C. Liu, A. M. Storniolo, M. F. Rimawi, A. Forero-Torres, A. C. Wolff, T. J. Hobday, A. Ivanova, W. K. Chiu, M. Ferraro, E. Burrows, P. S. Bernard, K. A. Hoadley, C. M. Perou, and E. P. Winer, “TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer,” J. Clin. Oncol. 30(21), 2615–2623 (2012).
[Crossref] [PubMed]

Wolff, A. C.

L. A. Carey, H. S. Rugo, P. K. Marcom, E. L. Mayer, F. J. Esteva, C. X. Ma, M. C. Liu, A. M. Storniolo, M. F. Rimawi, A. Forero-Torres, A. C. Wolff, T. J. Hobday, A. Ivanova, W. K. Chiu, M. Ferraro, E. Burrows, P. S. Bernard, K. A. Hoadley, C. M. Perou, and E. P. Winer, “TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer,” J. Clin. Oncol. 30(21), 2615–2623 (2012).
[Crossref] [PubMed]

Wu, C.

Q. Zhang, N. Iwakuma, P. Sharma, B. M. Moudgil, C. Wu, J. McNeill, H. Jiang, and S. R. Grobmyer, “Gold nanoparticles as a contrast agent for in vivo tumor imaging with photoacoustic tomography,” Nanotechnology 20(39), 395102 (2009).
[Crossref] [PubMed]

Wu, J. M.

J. M. Wu, M. J. Fackler, M. K. Halushka, D. W. Molavi, M. E. Taylor, W. W. Teo, C. Griffin, J. Fetting, N. E. Davidson, A. M. De Marzo, J. L. Hicks, D. Chitale, M. Ladanyi, S. Sukumar, and P. Argani, “Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases,” Clin. Cancer Res. 14(7), 1938–1946 (2008).
[Crossref] [PubMed]

Xia, Y.

X. Cai, W. Li, C. H. Kim, Y. Yuan, L. V. Wang, and Y. Xia, “In vivo quantitative evaluation of the transport kinetics of gold nanocages in a lymphatic system by noninvasive photoacoustic tomography,” ACS Nano 5(12), 9658–9667 (2011).
[Crossref] [PubMed]

Yarden, Y.

D. A. Ferraro, N. Gaborit, R. Maron, H. Cohen-Dvashi, Z. Porat, F. Pareja, S. Lavi, M. Lindzen, N. Ben-Chetrit, M. Sela, and Y. Yarden, “Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR,” Proc. Natl. Acad. Sci. U.S.A. 110(5), 1815–1820 (2013).
[Crossref] [PubMed]

Yaszemski, M. J.

C. R. Patra, R. Bhattacharya, E. Wang, A. Katarya, J. S. Lau, S. Dutta, M. Muders, S. Wang, S. A. Buhrow, S. L. Safgren, M. J. Yaszemski, J. M. Reid, M. M. Ames, P. Mukherjee, and D. Mukhopadhyay, “Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent,” Cancer Res. 68(6), 1970–1978 (2008).
[Crossref] [PubMed]

Yeager, D.

G. P. Luke, D. Yeager, and S. Y. Emelianov, “Biomedical applications of photoacoustic imaging with exogenous contrast agents,” Ann. Biomed. Eng. 40(2), 422–437 (2012).
[Crossref] [PubMed]

Yuan, Y.

X. Cai, W. Li, C. H. Kim, Y. Yuan, L. V. Wang, and Y. Xia, “In vivo quantitative evaluation of the transport kinetics of gold nanocages in a lymphatic system by noninvasive photoacoustic tomography,” ACS Nano 5(12), 9658–9667 (2011).
[Crossref] [PubMed]

Zhang, Q.

Q. Zhang, N. Iwakuma, P. Sharma, B. M. Moudgil, C. Wu, J. McNeill, H. Jiang, and S. R. Grobmyer, “Gold nanoparticles as a contrast agent for in vivo tumor imaging with photoacoustic tomography,” Nanotechnology 20(39), 395102 (2009).
[Crossref] [PubMed]

ACS Nano (2)

X. Cai, W. Li, C. H. Kim, Y. Yuan, L. V. Wang, and Y. Xia, “In vivo quantitative evaluation of the transport kinetics of gold nanocages in a lymphatic system by noninvasive photoacoustic tomography,” ACS Nano 5(12), 9658–9667 (2011).
[Crossref] [PubMed]

J. Chen and J. Irudayaraj, “Quantitative investigation of compartmentalized dynamics of ErbB2 targeting gold nanorods in live cells by single molecule spectroscopy,” ACS Nano 3(12), 4071–4079 (2009).
[Crossref] [PubMed]

Ann. Biomed. Eng. (1)

G. P. Luke, D. Yeager, and S. Y. Emelianov, “Biomedical applications of photoacoustic imaging with exogenous contrast agents,” Ann. Biomed. Eng. 40(2), 422–437 (2012).
[Crossref] [PubMed]

Ann. Oncol. (1)

R. Rönkä, K. Smitten, H. Sintonen, T. Kotomäki, L. Krogerus, E. Leppänen, and M. Leidenius, “The impact of sentinel node biopsy and axillary staging strategy on hospital costs,” Ann. Oncol. 15(1), 88–94 (2004).
[Crossref] [PubMed]

BMC Med. Imaging (1)

M. M. Jensen, J. T. Jørgensen, T. Binderup, and A. Kjaer, “Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper,” BMC Med. Imaging 8(1), 16 (2008).
[Crossref] [PubMed]

Br. J. Radiol. (1)

S. Jain, D. G. Hirst, and J. M. O’Sullivan, “Gold nanoparticles as novel agents for cancer therapy,” Br. J. Radiol. 85(1010), 101–113 (2012).
[Crossref] [PubMed]

Br. J. Surg. (1)

L. Bergkvist, J. Frisell, G. Swedish, Swedish Breast Cancer GroupSwedish Society of Breast Surgeons, “Multicentre validation study of sentinel node biopsy for staging in breast cancer,” Br. J. Surg. 92(10), 1221–1224 (2005).
[Crossref] [PubMed]

Cancer Res. (2)

G. P. Luke, J. N. Myers, S. Y. Emelianov, and K. V. Sokolov, “Sentinel lymph node biopsy revisited: ultrasound-guided photoacoustic detection of micrometastases using molecularly targeted plasmonic nanosensors,” Cancer Res. 74(19), 5397–5408 (2014).
[Crossref] [PubMed]

C. R. Patra, R. Bhattacharya, E. Wang, A. Katarya, J. S. Lau, S. Dutta, M. Muders, S. Wang, S. A. Buhrow, S. L. Safgren, M. J. Yaszemski, J. M. Reid, M. M. Ames, P. Mukherjee, and D. Mukhopadhyay, “Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent,” Cancer Res. 68(6), 1970–1978 (2008).
[Crossref] [PubMed]

Chem. Soc. Rev. (1)

N. Khlebtsov and L. Dykman, “Biodistribution and toxicity of engineered gold nanoparticles: a review of in vitro and in vivo studies,” Chem. Soc. Rev. 40(3), 1647–1671 (2011).
[Crossref] [PubMed]

Clin. Cancer Res. (1)

J. M. Wu, M. J. Fackler, M. K. Halushka, D. W. Molavi, M. E. Taylor, W. W. Teo, C. Griffin, J. Fetting, N. E. Davidson, A. M. De Marzo, J. L. Hicks, D. Chitale, M. Ladanyi, S. Sukumar, and P. Argani, “Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases,” Clin. Cancer Res. 14(7), 1938–1946 (2008).
[Crossref] [PubMed]

Contrast Media Mol. Imaging (1)

S. Manohar, C. Ungureanu, and T. G. Van Leeuwen, “Gold nanorods as molecular contrast agents in photoacoustic imaging: the promises and the caveats,” Contrast Media Mol. Imaging 6(5), 389–400 (2011).
[Crossref] [PubMed]

Curr. Treat. Options Oncol. (1)

F. Amersi and N. M. Hansen, “The benefits and limitations of sentinel lymph node biopsy,” Curr. Treat. Options Oncol. 7(2), 141–151 (2006).
[Crossref] [PubMed]

J. Clin. Oncol. (1)

L. A. Carey, H. S. Rugo, P. K. Marcom, E. L. Mayer, F. J. Esteva, C. X. Ma, M. C. Liu, A. M. Storniolo, M. F. Rimawi, A. Forero-Torres, A. C. Wolff, T. J. Hobday, A. Ivanova, W. K. Chiu, M. Ferraro, E. Burrows, P. S. Bernard, K. A. Hoadley, C. M. Perou, and E. P. Winer, “TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer,” J. Clin. Oncol. 30(21), 2615–2623 (2012).
[Crossref] [PubMed]

J. Natl. Cancer Inst. (1)

H. Kobayashi, S. Kawamoto, Y. Sakai, P. L. Choyke, R. A. Star, M. W. Brechbiel, N. Sato, Y. Tagaya, J. C. Morris, and T. A. Waldmann, “Lymphatic drainage imaging of breast cancer in mice by micro-magnetic resonance lymphangiography using a nano-size paramagnetic contrast agent,” J. Natl. Cancer Inst. 96(9), 703–708 (2004).
[Crossref] [PubMed]

Nano Lett. (1)

M. Eghtedari, A. Oraevsky, J. A. Copland, N. A. Kotov, A. Conjusteau, and M. Motamedi, “High sensitivity of in vivo detection of gold nanorods using a laser optoacoustic imaging system,” Nano Lett. 7(7), 1914–1918 (2007).
[Crossref] [PubMed]

Nanotechnology (1)

Q. Zhang, N. Iwakuma, P. Sharma, B. M. Moudgil, C. Wu, J. McNeill, H. Jiang, and S. R. Grobmyer, “Gold nanoparticles as a contrast agent for in vivo tumor imaging with photoacoustic tomography,” Nanotechnology 20(39), 395102 (2009).
[Crossref] [PubMed]

Nat. Rev. Drug Discov. (1)

J. Graham, M. Muhsin, and P. Kirkpatrick, “Cetuximab,” Nat. Rev. Drug Discov. 3(7), 549–550 (2004).
[Crossref] [PubMed]

Opt. Express (1)

Proc. Natl. Acad. Sci. U.S.A. (1)

D. A. Ferraro, N. Gaborit, R. Maron, H. Cohen-Dvashi, Z. Porat, F. Pareja, S. Lavi, M. Lindzen, N. Ben-Chetrit, M. Sela, and Y. Yarden, “Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR,” Proc. Natl. Acad. Sci. U.S.A. 110(5), 1815–1820 (2013).
[Crossref] [PubMed]

Radiology (1)

G. P. Luke and S. Y. Emelianov, “Label-free Detection of Lymph Node Metastases with US-guided Functional Photoacoustic Imaging,” Radiology 277(2), 435–442 (2015).
[Crossref] [PubMed]

Science (1)

L. V. Wang and S. Hu, “Photoacoustic tomography: in vivo imaging from organelles to organs,” Science 335(6075), 1458–1462 (2012).
[Crossref] [PubMed]

Cited By

OSA participates in Crossref's Cited-By Linking service. Citing articles from OSA journals and other participating publishers are listed here.

Alert me when this article is cited.


Figures (4)

Fig. 1
Fig. 1 Analysis of US-guided photoacoustic (PA) images and histology of the axillary LN of mice injected with ICG or gold nanorods (GN). (a) Non-invasive and dynamic fusion of US and PA images of the axillary LN region before and 0.5 h, 1 h, 2 h, 4 h and 24 h after ICG injection (5 pmol/g mouse). (b) Plot of PA signal amplitude in axillary LNs versus pre- and post-injection time of ICG. (c) Non-invasive and dynamical fusion of US and PA images of axillary LN region before and 4, 12 h, 24 h, 48 h and 72 h after GN injection (0.005 pmol/g mouse). (d) Plot of PA signal amplitude in axillary LNs versus pre- and post-injection time of GN. The results represent the mean ± standard deviation in the ICG-mice group (n = 5) and the GN-mice group (n = 5), *p<0.05, **p<0.01, Arbitrary units (AU). (e, f) Photographs of isolated axillary LN before and after injection of ICG or GN. (g) H&E staining of microsectioned axillary LN isolated from mice 4 h post-injection of ICG. (h) H&E staining and silver staining of microsectioned axillary LN isolated from mice at 48 h post-injection of GN. The control (Cont) is a microsectioned axillary LN without injection of ICG or GN. Scale bar: 100 μm.
Fig. 2
Fig. 2 Analysis of EGFR expression in human breast cancer cell lines and US-guided PAI and histology acquired in MCF-7 and MDA-MB-231 primary tumors of mice intravenously injected with anti-EGFR-GNs. (a) EGFR expression in MCF-7, BT-474, HCC-1954, HCC-1937, MDA-MB-453 and MDA-MB-231 human breast cancer cell lines (by western blot). (b) Silver staining of MCF-7 and MDA-MB-231 cells incubated with or without 120pmol/L of anti-EGFR-GNs for 24 h. Control (Cont) was incubated without 120pmol/L of anti-EGFR-GNs. (c) Non-invasive and dynamical fusion of US and PA images of MCF-7 and MDA-MB-231 tumors before and 2 h, 4 h, 8 h, 24 h, 48 h and 72 h after intravenous injection with anti-EGFR-GNs (0.5 pmol/g mouse). (d) Plot of PA signal amplitude in MCF-7 and MDA-MB-231 tumors versus pre- and post-injection of anti-EGFR-GNs. The results represent the mean ± standard deviation in the MCF-7-mice group (n = 5) and MDA-MB-231-mice group (n = 5). **p<0.01, Arbitrary units (AU). (e) H&E staining, EGFR immunostaining and silver staining of microsectioned MDA-MB-231 and MCF-7 primary tumors isolated from mice 48 h post-injection of anti-EGFR GN. Scale bar: 100 μm.
Fig. 3
Fig. 3 Analysis of US-guided PAI and histology acquired in MCF-7 and MDA-MB-231 primary tumors of mice intravenously injected with non-targeted GNs. (a) Non-invasive and dynamical fusion of US and PA images of MCF-7 and MDA-MB-231 tumors before and 2 h, 4 h, 8 h, 24 h, 48 h and 72 h after intravenous injection with non-targeted GNs (0.5pmol/g mouse). (b) Plot of PA signal amplitude in MCF-7 and MDA-MB-231 tumors versus pre-and post-injection of non-targeted GNs. The results represented the mean ± standard deviation in the MCF-7-mice group (n = 5) and MDA-MB-231-mice group (n = 5). **p<0.01, Arbitrary units (AU). (c) H&E staining and silver staining of microsectioned MDA-MB-231 and MCF-7 primary tumor isolated from mice 48 h post-injection of non-targeted GNs. Scale bar: 100 μm.
Fig. 4
Fig. 4 Analysis of US-guided PAI and histology acquired in LN metastases of MDA-MB-231-Luc tumor-bearing mice injected with anti-EGFR-GNs into the primary tumor. (a, b) Non-invasive and dynamical fusion of US and PA images of axillary LN metastases and non-LN metastases in MDA-MB-231-Luc tumor-bearing mice 24 h after intratumoral injection with anti-EGFR-GNs (0.5 pmol/g mouse). (c) Plot of PA signal amplitude in axillary LN at pre- and post-injection of anti-EGFR-GNs. The results represent the mean ± standard deviation in the LN metastases mice group (n = 2) and non-LN metastases mice group (n = 4), Arbitrary units (AU). (d) In vivo (left) and ex vivo (right) bioluminescence imaging of MDA-MB-231-Luc tumor-bearing mice injected intraperitoneally with D-luciferin (150 μg/g mouse). Red and white circles indicate the excised primary tumor and axillary LN from ex vivo bioluminescence imaging. (e, f) H&E staining, EGFR and cytokeratin 8/18/19 immunostaining and silver staining of microsectioned axillary LNs isolated from mice at 48 h post-injection of anti-EGFR GNs. Scale bar: 100 μm.

Metrics